Merz Pharma GmbH

Timely additions to leadership team and board of directors align with company's initiation of first-in-human clinical studies of novel HYALEX® Cartilage Platform LEXINGTON, Mich., April 15, 2024 /PRNewswire/ -- Hyalex Orthopaedics, a privately held medical device company developing cartilage repair products based on the transformative HYALEX® materials platform, today announced the appointment of Thomas "Tad" Vail, M.D., as chief medical officer. Dr. Vail is internationally recognized as a specialist in total and partial joint replacement and surgical treatment of hip and knee conditions, having most recently served as the Michael and Antoinette Pappas endowed chair and James L. Young professor of orthopaedic surgery at the University of California, San Francisco (UCSF). Additionally, Hyalex announced the appointment of Adam Gridley, the chief executive officer of Allay Therapeutics, to the company's board of directors. These two appointments significantly augment the scientific and operational expertise of the Hyalex team at a time when the company is bringing its novel HYALEX Cartilage platform into first-in-human clinical trials. "Hyalex is entering an exciting and transformational period for the company, as we advance our novel HYALEX Cartilage platform into the clinic for the first time. By adding Tad's deep scientific and clinical expertise in the orthopaedics field, along with Adam's impressive operational and transactional track record in the biotech and medical device space, we are significantly elevating the company's leadership to best position Hyalex for success," said Carl Vause, Hyalex's president and chief executive officer. "We look forward to the important contributions that both Tad and Adam will make to the success of the company." Prior to stepping down in 2023, Dr. Vail had served as chair of orthopaedic surgery at UCSF since 2007, helping to establish the department as an international leader in patient care, research, education, and global health. His research focuses on performance and outcomes of surgical procedures and devices, delivery of care in adult reconstruction, and cartilage repair strategies. He has published several hundred scientific articles, abstracts, book chapters and educational materials on many facets of hip and knee surgery, surgical training and innovation, health economics, and patient care. He is the past president of the Knee Society, the American Association of Hip and Knee Surgeons, and the Eastern Orthopaedic Association, past vice president of the American Board of Orthopaedic Surgery, and currently sits on the board of trustees for the Journal of Bone and Joint Surgery. Additionally, Dr. Vail has multiple patents for orthopaedic devices and has served as an industry consultant, participated on multiple scientific advisory boards, and helped to start companies in the musculoskeletal device space. "During my more than 16 years leading the orthopaedics department at UCSF, I was fortunate to have a front row seat to many of the most promising innovations in joint reconstruction and cartilage repair. With my perspective on the evolution of the field, along with an understanding of the ongoing unmet needs of patients in this area, I believe that the technology being advanced by Hyalex has an opportunity to be a true game changer," said Dr. Vail. "This platform has the potential to offer patients a joint restoration treatment that mimics the properties of natural cartilage in distinction to traditional orthopaedic materials. HYALEX Cartilage is designed to accelerate recovery from cartilage injury and degeneration, either as an alternative to biologic therapy or in combination. The opportunity to play a role in such a potentially significant advance in patient care was too exciting for me to pass up." Mr. Gridley has over 25 years experience in the biotechnology, medical device and pharmaceutical industries leading venture capital-backed startups to fully integrated public commercial organizations. He is the CEO of Allay Therapeutics, a drug delivery biotechnology company, and previously was the CEO of Entera Bio, a biotechnology company specializing in the oral delivery of large molecules and biologics, as well as the CEO of Histogenics, a cell therapy and biologics company developing novel therapeutics for cartilage defects. At Histogenics, he led its IPO, multiple fundraisings and strategic transactions, and oversaw several successful clinical and manufacturing initiatives for the company's Phase 3 trial of NeoCart. Prior to Histogenics, Mr. Gridley held several corporate and operational executive roles at Merz Pharma and BioForm Medical (including the sale to Merz), where he played a key role in an IPO as well as acquisitions and product launches. Mr. Gridley has served on the board of directors of LifeSprout and the Alliance for Regenerative Medicine (ARM) and is on the board of advisors for Life Science Cares Bay Area. "Having worked in the life science sector for more than two decades, including holding senior positions within innovative biotechnology and medical device companies, it is clear to me that Hyalex is strongly positioned to make a significant impact on patient care with its synthetic cartilage platform," said Mr. Gridley. "Simple yet effective cartilage repair solutions are still one of the largest unmet needs in orthopaedics for a broad demographic of patients seeking rapid recuperation and pain relief. Given the potential for the company's technology platform, I'm excited to join the Hyalex board and talented team and share my experiences in the cartilage repair and fundraising space as they work diligently to deliver innovative new therapeutic options for patients who are suffering with damaged and diseased joints." About Hyalex Orthopaedics Hyalex is a privately held medical device company headquartered in Lexington, MA, developing transformational synthetic cartilage technology and implant systems for diseased and damaged joints. HYALEX Cartilage is protected by more than 17 patents and trademarks worldwide. The HYALEX Cartilage platform has received Investigational Device Exemption (IDE) approval from the United States Food and Drug Administration for a clinical trial in the United States. Hyalex is initiating first-in-human clinical studies of HYALEX Cartilage for knee cartilage repair in both the U.S. and Europe. For more information: Contact Information: Tim Brons Vida Strategic Partners (media) 646-319-8981 [email protected] SOURCE Hyalex Orthopaedics

Strategic Leadership Appointments to Propel Global Growth RALEIGH, N.C., April 11, 2024 /PRNewswire/ -- ProPharma, the leading global provider of regulatory, clinical, and compliance services for the life sciences industry and a portfolio company of Odyssey Investment Partners is pleased to announce that it has welcomed Kirk Wroblewski as its new Chief Information Officer (CIO) and Andrew Shaw as General Counsel. In addition, ProPharma has promoted Zosya Popik to Chief Marketing Officer (CMO), previously the Vice President of Global Marketing. Continue Reading "We are thrilled to welcome Kirk and Andrew to the executive team and to elevate Zosya as our new Chief Marketing Officer," said Mike Stomberg, Chief Executive Officer. "The combined expertise of each of these team members positions ProPharma to transcend in the industry and continue to compete on a global scale." ProPharma Announces Changes to Its Executive Leadership Team to Propel Global Growth Post this Wroblewski is a highly accomplished, solutions-focused information executive with more than 20 years of experience in healthcare data and analytics. He recently served as the Chief Data Officer for Healthfirst, where he helped build out the near-term and future technical roadmap to match the business goals at the heart of the problems in healthcare. In addition, he held leadership roles at Rainfall Health, Deloitte Digital, Merz Pharma, LabCorp and GSK. "ProPharma helps companies advance at every stage of the pharmaceutical lifecycle and is truly an industry leader," said Wroblewski. "As the new CIO, I'm ready to use my data and analytics expertise to ensure that the staff and technologies within ProPharma's IT department deliver outcomes that support the mission of the business." Popik brings more than 16 years of diverse marketing experience across Fortune 300 companies, fast-moving startups, and the CPG and life sciences industry to her role at ProPharma. She recently led ProPharma's rebranding and repositioning initiative. Prior to joining ProPharma, Zosya held leadership roles across Fortune 300 companies where she built and scaled digital marketing teams from the ground up and spearheaded social media & digital efforts for Icon plc (formerly PRA Health Sciences). She will continue to oversee strategic performance marketing, branding, marketing tech stack, and global communications. "The opportunity to lead and integrate my experiences in digital transformation, global branding, and digital growth at such a pivotal time for ProPharma is both an honor and a challenge I eagerly embrace," said Popik. "In my new position as CMO, I look forward to continue advancing ProPharma's role as the world's largest research consulting organization (RCO)." Shaw serves as General Counsel of ProPharma, where he oversees the global legal function. He has more than 20 years of Life Science experience from both private practice and as in-house counsel. Before joining ProPharma, Shaw led the global legal team at Perspectum Ltd, a UK-based medical device company. He also held senior leadership positions within the legal departments at Fortrea and Syneos Health. Prior to that, he spent eight years in private practice, where he specialized in complex commercial contracting, private equity M&A, and public company transactions. "It's an honor to join a company at the forefront of life sciences, committed to pioneering research and development that advances global health," said Shaw. "I look forward to providing legal and operational excellence to support ProPharma as it continues to deliver impactful healthcare solutions and innovations to the industry." About ProPharma For the past 20 years, ProPharma has improved the health and wellness of patients by providing advice and expertise that empowers biotech, med device, and pharmaceutical organizations of all sizes to confidently advance scientific breakthroughs and introduce new therapies. As the world's largest RCO (Research Consulting Organization), ProPharma partners with its clients through an advise-build-operate model across the complete product lifecycle. With deep domain expertise in regulatory sciences, clinical research solutions, quality and compliance, pharmacovigilance, medical information, and R&D technology, ProPharma offers an end-to-end suite of fully customizable consulting solutions that de-risk and accelerate our partners' most high-profile drug and device programs. For more information about ProPharma, please visit: . About Odyssey Investment Partners Odyssey Investment Partners, with offices in New York and Los Angeles, is a leading private equity investment firm with more than a 25-year history of partnering with skilled managers to transform middle-market companies into more efficient and diversified businesses with strong growth profiles. Odyssey makes majority-controlled investments in industries with a long-term positive outlook and favorable secular trends. For further information about Odyssey, please visit:  . SOURCE ProPharma Group Holdings LLC

NEW YORK, Jan. 11, 2023 /PRNewswire/ -- The aesthetic devices market in France by product, end-user and distribution channel - forecast and analysis 2023-2027 report has been published by Technavio. Market growth is estimated to accelerate at a CAGR of 10.22% and register an incremental growth of USD 237.05 million during the forecast period. The report provides a comprehensive analysis of growth opportunities at regional levels, new product launches, the latest trends, and the post-pandemic recovery of the global market. Download a PDF sample report Company profiles Continue Reading Technavio has announced its latest market research report titled France Aesthetic Devices Market 2023-2027 The aesthetic devices market report in France includes information on the key products and recent developments of leading vendors, including: AbbVie Inc. - The company offers aesthetic devices under the subsidiary Allergan. Alma Lasers GmbH - The company offers aesthetic devices such as Soprano Titanium, Soprano ICE Platinum, and Alma PrimeX. Candela Corp - The company offers aesthetic devices such as the SaltFacial. Cutera Inc. - The company offers aesthetic devices such as Xeo, Excel HR, and Enlighten SR. Cynosure LLC Fotona d.o.o Lumenis Be Ltd Merz Pharma GmbH and Co KGaA Sciton Inc. Venus Concept Inc. To gain access to more vendor profiles available with Technavio, buy the report! Market Dynamics The market is driven by factors such as a rise in awareness regarding aesthetic surgeries, a growing number of private clinics and treatment options will be crucial in driving the growth of the market. However, the stringent regulation on aesthetic devices is hindering the market growth. Competitive Analysis The competitive scenario categorizes companies based on various performance indicators. Some of the factors considered include the financial performance of companies over the past few years, growth strategies, product innovations, new product launches, investments, and growth in market share, among others. Request a sample Market Segmentation Based on product, the market is segmented into energy-based aesthetic devices and non-energy-based aesthetic devices. The energy-based aesthetic devices segment accounted for the largest share of the market in 2022. Related Reports: The energy-based aesthetic devices market is estimated to grow at a CAGR of 8.5% between 2022 and 2027. The size of the market is forecast to increase by USD 1,752 million. The increasing demand for aesthetic procedures is notably driving the market growth, although factors such as risks associated with energy-based aesthetic devices may impede the market growth. The aesthetic devices market is estimated to grow at a CAGR of 11.22% between 2022 and 2027. The size of the market is forecasted to increase by USD 10,815.68 million. The shifting consumer attitudes about wellness and beauty are notably driving the market growth, although factors such as stringent regulation on aesthetic devices may impede the market growth. Technavio's library includes over 17,000+ reports, covering more than 2,000 emerging technologies. Subscribe to our "Basic Plan" at just USD 5,000 and get lifetime access to Technavio Insights What are the Key Data Covered in this Aesthetic Devices Market Report In France? CAGR of the market during the forecast period Detailed information on factors that will drive the growth of the aesthetic devices market between 2023 and 2027 Precise estimation of the aesthetic devices market size in France and its contribution to the market in focus on the parent market Accurate predictions about upcoming trends and changes in consumer behavior Growth of the industry across France A thorough analysis of the market's competitive landscape and detailed information about vendors Comprehensive analysis of factors that will challenge the growth of aesthetic devices market vendors in France Browse for Technavio's health care market reports Table of Contents: 1 Executive Summary 1.1 Market overview Exhibit 01: Executive Summary – Chart on Market Overview Exhibit 02: Executive Summary – Data Table on Market Overview Exhibit 03: Executive Summary – Chart on Country Market Characteristics Exhibit 04: Executive Summary – Chart on Market Segmentation by Product Exhibit 05: Executive Summary – Chart on Market Segmentation by End-user Exhibit 06: Executive Summary – Chart on Market Segmentation by Distribution Channel Exhibit 07: Executive Summary – Chart on Vendor Market Positioning 2 Market Landscape 2.1 Market ecosystem Exhibit 08: Parent market Exhibit 09: Market Characteristics 3 Market Sizing 3.1 Market definition Exhibit 10: Offerings of vendors included in the market definition 3.2 Market segment analysis Exhibit 11: Market segments 3.3 Market size 2022 3.4 Market outlook: Forecast for 2022-2027 Exhibit 12: Chart on France - Market size and forecast 2022-2027 ($ million) Exhibit 13: Data Table on France - Market size and forecast 2022-2027 ($ million) Exhibit 14: Chart on France: Year-over-year growth 2022-2027 (%) Exhibit 15: Data Table on France: Year-over-year growth 2022-2027 (%) 4 Historic Market Size 4.1 Aesthetic devices market in France 2017 - 2021 Exhibit 16: Historic Market Size – Data Table on Aesthetic devices market in France 2017 - 2021 ($ million) 4.2 Product Segment Analysis 2017 - 2021 Exhibit 17: Historic Market Size – Product Segment 2017 - 2021 ($ million) 4.3 End-user Segment Analysis 2017 - 2021 Exhibit 18: Historic Market Size – End-user Segment 2017 - 2021 ($ million) 4.4 Distribution channel Segment Analysis 2017 - 2021 Exhibit 19: Historic Market Size – Distribution channel Segment 2017 - 2021 ($ million) 5 Five Forces Analysis 5.1 Five forces summary Exhibit 20: Five forces analysis - Comparison between 2022 and 2027 5.2 Bargaining power of buyers Exhibit 21: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027 5.3 Bargaining power of suppliers Exhibit 22: Bargaining power of suppliers – Impact of key factors in 2022 and 2027 5.4 Threat of new entrants Exhibit 23: Threat of new entrants – Impact of key factors in 2022 and 2027 5.5 Threat of substitutes Exhibit 24: Threat of substitutes – Impact of key factors in 2022 and 2027 5.6 Threat of rivalry Exhibit 25: Threat of rivalry – Impact of key factors in 2022 and 2027 5.7 Market condition Exhibit 26: Chart on Market condition - Five forces 2022 and 2027 6 Market Segmentation by Product 6.1 Market segments Exhibit 27: Chart on Product - Market share 2022-2027 (%) Exhibit 28: Data Table on Product - Market share 2022-2027 (%) 6.2 Comparison by Product Exhibit 29: Chart on Comparison by Product Exhibit 30: Data Table on Comparison by Product 6.3 Energy-based aesthetic devices - Market size and forecast 2022-2027 Exhibit 31: Chart on Energy-based aesthetic devices - Market size and forecast 2022-2027 ($ million) Exhibit 32: Data Table on Energy-based aesthetic devices - Market size and forecast 2022-2027 ($ million) Exhibit 33: Chart on Energy-based aesthetic devices - Year-over-year growth 2022-2027 (%) Exhibit 34: Data Table on Energy-based aesthetic devices - Year-over-year growth 2022-2027 (%) 6.4 Non energy-based aesthetic devices - Market size and forecast 2022-2027 Exhibit 35: Chart on Non energy-based aesthetic devices - Market size and forecast 2022-2027 ($ million) Exhibit 36: Data Table on Non energy-based aesthetic devices - Market size and forecast 2022-2027 ($ million) Exhibit 37: Chart on Non energy-based aesthetic devices - Year-over-year growth 2022-2027 (%) Exhibit 38: Data Table on Non energy-based aesthetic devices - Year-over-year growth 2022-2027 (%) 6.5 Market opportunity by Product Exhibit 39: Market opportunity by Product ($ million) 7 Market Segmentation by End-user 7.1 Market segments Exhibit 40: Chart on End-user - Market share 2022-2027 (%) Exhibit 41: Data Table on End-user - Market share 2022-2027 (%) 7.2 Comparison by End-user Exhibit 42: Chart on Comparison by End-user Exhibit 43: Data Table on Comparison by End-user 7.3 Hospitals - Market size and forecast 2022-2027 Exhibit 44: Chart on Hospitals - Market size and forecast 2022-2027 ($ million) Exhibit 45: Data Table on Hospitals - Market size and forecast 2022-2027 ($ million) Exhibit 46: Chart on Hospitals - Year-over-year growth 2022-2027 (%) Exhibit 47: Data Table on Hospitals - Year-over-year growth 2022-2027 (%) 7.4 Dermatology clinics - Market size and forecast 2022-2027 Exhibit 48: Chart on Dermatology clinics - Market size and forecast 2022-2027 ($ million) Exhibit 49: Data Table on Dermatology clinics - Market size and forecast 2022-2027 ($ million) Exhibit 50: Chart on Dermatology clinics - Year-over-year growth 2022-2027 (%) Exhibit 51: Data Table on Dermatology clinics - Year-over-year growth 2022-2027 (%) 7.5 Others - Market size and forecast 2022-2027 Exhibit 52: Chart on Others - Market size and forecast 2022-2027 ($ million) Exhibit 53: Data Table on Others - Market size and forecast 2022-2027 ($ million) Exhibit 54: Chart on Others - Year-over-year growth 2022-2027 (%) Exhibit 55: Data Table on Others - Year-over-year growth 2022-2027 (%) 7.6 Market opportunity by End-user Exhibit 56: Market opportunity by End-user ($ million) 8 Market Segmentation by Distribution Channel 8.1 Market segments Exhibit 57: Chart on Distribution Channel - Market share 2022-2027 (%) Exhibit 58: Data Table on Distribution Channel - Market share 2022-2027 (%) 8.2 Comparison by Distribution Channel Exhibit 59: Chart on Comparison by Distribution Channel Exhibit 60: Data Table on Comparison by Distribution Channel 8.3 Offline - Market size and forecast 2022-2027 Exhibit 61: Chart on Offline - Market size and forecast 2022-2027 ($ million) Exhibit 62: Data Table on Offline - Market size and forecast 2022-2027 ($ million) Exhibit 63: Chart on Offline - Year-over-year growth 2022-2027 (%) Exhibit 64: Data Table on Offline - Year-over-year growth 2022-2027 (%) 8.4 Online - Market size and forecast 2022-2027 Exhibit 65: Chart on Online - Market size and forecast 2022-2027 ($ million) Exhibit 66: Data Table on Online - Market size and forecast 2022-2027 ($ million) Exhibit 67: Chart on Online - Year-over-year growth 2022-2027 (%) Exhibit 68: Data Table on Online - Year-over-year growth 2022-2027 (%) 8.5 Market opportunity by Distribution Channel Exhibit 69: Market opportunity by Distribution Channel ($ million) 9 Customer Landscape 9.1 Customer landscape overview Exhibit 70: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria 10 Drivers, Challenges, and Trends 10.1 Market drivers 10.2 Market challenges 10.3 Impact of drivers and challenges Exhibit 71: Impact of drivers and challenges in 2022 and 2027 10.4 Market trends 11 Vendor Landscape 11.1 Overview 11.2 Vendor landscape Exhibit 72: Overview on Criticality of inputs and Factors of differentiation 11.3 Landscape disruption Exhibit 73: Overview on factors of disruption 11.4 Industry risks Exhibit 74: Impact of key risks on business 12 Vendor Analysis 12.1 Vendors covered Exhibit 75: Vendors covered 12.2 Market positioning of vendors Exhibit 76: Matrix on vendor position and classification 12.3 AbbVie Inc. Exhibit 77: AbbVie Inc. - Overview Exhibit 78: AbbVie Inc. - Product / Service Exhibit 79: AbbVie Inc. - Key news Exhibit 80: AbbVie Inc. - Key offerings 12.4 Alma Lasers GmbH Exhibit 81: Alma Lasers GmbH - Overview Exhibit 82: Alma Lasers GmbH - Product / Service Exhibit 83: Alma Lasers GmbH - Key offerings 12.5 Candela Corp Exhibit 84: Candela Corp - Overview Exhibit 85: Candela Corp - Product / Service Exhibit 86: Candela Corp - Key offerings 12.6 Cutera Inc. Exhibit 87: Cutera Inc. - Overview Exhibit 88: Cutera Inc. - Product / Service Exhibit 89: Cutera Inc. - Key offerings 12.7 Cynosure LLC Exhibit 90: Cynosure LLC - Overview Exhibit 91: Cynosure LLC - Product / Service Exhibit 92: Cynosure LLC - Key offerings 12.8 Fotona d.o.o Exhibit 93: Fotona d.o.o - Overview Exhibit 94: Fotona d.o.o - Product / Service Exhibit 95: Fotona d.o.o - Key offerings 12.9 Lumenis Be Ltd Exhibit 96: Lumenis Be Ltd - Overview Exhibit 97: Lumenis Be Ltd - Product / Service Exhibit 98: Lumenis Be Ltd - Key offerings 12.10 Merz Pharma GmbH and Co KGaA Exhibit 99: Merz Pharma GmbH and Co KGaA - Overview Exhibit 100: Merz Pharma GmbH and Co KGaA - Product / Service Exhibit 101: Merz Pharma GmbH and Co KGaA - Key offerings 12.11 Sciton Inc. Exhibit 102: Sciton Inc. - Overview Exhibit 103: Sciton Inc. - Product / Service Exhibit 104: Sciton Inc. - Key offerings 12.12 Venus Concept Inc. Exhibit 105: Venus Concept Inc. - Overview Exhibit 106: Venus Concept Inc. - Product / Service Exhibit 107: Venus Concept Inc. - Key offerings 13 Appendix 13.1 Scope of the report 13.2 Inclusions and exclusions checklist Exhibit 108: Inclusions checklist Exhibit 109: Exclusions checklist 13.3 Currency conversion rates for US$ Exhibit 110: Currency conversion rates for US$ 13.4 Research methodology Exhibit 111: Research methodology Exhibit 112: Validation techniques employed for market sizing Exhibit 113: Information sources 13.5 List of abbreviations Exhibit 114: List of abbreviations About Us Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios. Contact Technavio Research Jesse Maida Media & Marketing Executive US: +1 844 364 1100 UK: +44 203 893 3200 Email: [email protected] Website: SOURCE Technavio